γ‐Secretase inhibitors (GSIs), originally developed as therapeutics for Alzheimer's disease based on their ability to reduce production of the amyloid β peptide, are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH1 signaling in select cancers is therapeutic. Here, NOTCH1 is linked to Alzheimer disease.